undamentalytics Newsletter
Sign in

Akanda Corp. (AKAN) stock

Add to watchlist

Add holding +

NASDAQ: AKAN Nasdaq Pharmaceuticals

E Fundamentals grade

Akanda Corp. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Akanda Corp. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: share count (0m) is 0.035x the cover-page count (2m). We'll show the comparison once resolved.

Akanda Corp. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling1 purchase and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds4 adding, 1 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Akanda files

Where Akanda stands after its latest Filing

Akanda has little or no product revenue yet; it used $8m of cash in the twelve months. That puts it 72 of 74 for growth among the pharmaceuticals companies we cover. The diluted share count is down 93.4% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 0 of our 3 financial-health checks.

Our model value for Akanda is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Akanda Corp.'s trailing-twelve-month revenue fell 69.2% year on year, with a free-cash-flow margin of -3085.6%. Where it stands out: change in share count of -93.4% ranks 2 of 62 pharmaceuticals companies we cover. Where it lags: days sales outstanding of 1980 days ranks 59 of 59 pharmaceuticals companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -69.2% (-166.6pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 93.4% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 69.2% over the last 12 months.
  • Growth slowing. The growth rate is 166.6 points lower than a quarter earlier.
  • Loss-making. Operating margin is -1931.0%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 1449.3 points on a year ago.
  • Burning cash. Free cash flow was -3085.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 21.3% of revenue: a real cost that cash-flow figures leave out.

Price chart

  • 1 day0.0%
  • 1 week-1.0%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$258,075
Operating margin
-1931.0%
Net margin
-467.1%
EPS (TTM, diluted)
$-17.48

Growth

Revenue growth
−69.2%
Change in growth rate
−166.6 pts
Share count change
−93.4%

Cash

Free cash flow (TTM)
-$8M
FCF margin
-3085.6%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for AKAN from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Akanda Corp. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: share count (0m) is 0.035x the cover-page count (2m): held for review.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Akanda Corp.: too few analysts cover it.

Positioning

Short interest
2.2%
of tradable shares
Days to cover
0.05
at average volume
Short interest, 1 month
+10%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
0.6%
of shares

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Akanda Corp. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Akanda Corp.
$0 $1M $2M $3M FY20 Q4 FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue (TTM), FY20 Q4: $2.1K Revenue (TTM), FY21 Q4: $41.4K Revenue (TTM), FY22 Q4: $2.6M Revenue (TTM), FY23 Q4: $423.7K Revenue (TTM), FY24 Q4: $836.7K Revenue (TTM), FY25 Q4: $258.1K $258.1K

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue (TTM)
FY20 Q4 $2.1K
FY21 Q4 $41.4K
FY22 Q4 $2.6M
FY23 Q4 $423.7K
FY24 Q4 $836.7K
FY25 Q4 $258.1K
Revenue growth, TTM YoY Akanda Corp.
-2000% 0% 2000% 4000% 6000% 8000% FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue growth, TTM YoY, FY21 Q4: 1909.3% Revenue growth, TTM YoY, FY22 Q4: 6223.0% Revenue growth, TTM YoY, FY23 Q4: -83.8% Revenue growth, TTM YoY, FY24 Q4: 97.5% Revenue growth, TTM YoY, FY25 Q4: -69.2% -69.2%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue growth, TTM YoY
FY21 Q4 1909.3%
FY22 Q4 6223.0%
FY23 Q4 -83.8%
FY24 Q4 97.5%
FY25 Q4 -69.2%
Operating margin (TTM) Akanda Corp.
-100000% -50000% 0% FY20 Q4 FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Operating margin (TTM), FY20 Q4: -80781.0% Operating margin (TTM), FY21 Q4: -6203.4% Operating margin (TTM), FY22 Q4: -770.2% Operating margin (TTM), FY23 Q4: -863.6% Operating margin (TTM), FY24 Q4: -481.7% Operating margin (TTM), FY25 Q4: -1931.0% -1931.0%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Operating margin (TTM)
FY20 Q4 -80781.0%
FY21 Q4 -6203.4%
FY22 Q4 -770.2%
FY23 Q4 -863.6%
FY24 Q4 -481.7%
FY25 Q4 -1931.0%
FCF margin (TTM) Akanda Corp.
-20000% -15000% -10000% -5000% 0% FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 FCF margin (TTM), FY21 Q4: -17217.9% FCF margin (TTM), FY22 Q4: -449.7% FCF margin (TTM), FY23 Q4: -354.5% FCF margin (TTM), FY24 Q4: -726.5% FCF margin (TTM), FY25 Q4: -3085.6% -3085.6%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q4 -17217.9%
FY22 Q4 -449.7%
FY23 Q4 -354.5%
FY24 Q4 -726.5%
FY25 Q4 -3085.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 0 0 3 0 1 0
Gross profit −0 −0 3 0 0 −0
EBITDA −1 −3 −17 −3 −4 −5
Operating income −2 −3 −20 −4 −4 −5
Net income −2 −8 −12 −32 −4 −1
Diluted EPS −$7.20 −$20.00 −$154.40 −$573.11 −$276.40 −$662.22
Growth (year on year)
Revenue — +>999% +>999% −83.8% +97.5% −69.2%
Margins
Gross margin <−999% −3.8% — 14.0% 24.9% −60.5%
EBITDA margin <−999% <−999% −632.8% −814.2% −465.3% <−999%
Operating margin <−999% <−999% −770.2% −863.6% −481.7% <−999%
Net margin <−999% <−999% −445.0% <−999% −489.6% −467.1%
Free-cash-flow margin — <−999% −449.7% −354.5% −726.5% <−999%
Cash flow
Cash from operations — −7 −11 −2 −4 −7
Capital spending 0 1 0 0 2 1
Free cash flow — −7 −12 −2 −6 −8
Stock-based pay — — 1 — — —
Free cash flow after stock pay — — −12 — — —
Balance sheet
Cash 0 3 0 0 4 1
Total debt 0 7 4 4 — 1
Net debt (negative = net cash) −0 3 3 4 −4 1
Diluted shares — — — — 1m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 3 checks passed · December 31, 2025
What it owns · $6m
Short-term assets $4mLonger-term assets $3m
What it owes, and who funded it · $18m
Short-term liabilities $6mLonger-term liabilities $12mShareholders' equity $-12m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $6m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $12m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$5m against $4,706 of interest.

From Akanda Corp.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
−93.4%
year over year
Days sales outstanding
1980 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated AKAN SCNX SXTP SXTC LPCN NTRB Median
Revenue, last 12 months $258075 $821315 $1m $1m $2m $2m $276m
Revenue growth, last 12 months −69.2% 540.6% 73.2% −34.6% −62.7% −37.3% 9.9%
Revenue growth, 3-year average — −58.5% 74.9% — 205.6% −10.8% 5.5%
Revenue growth, latest quarter — 449.1% 106.0% — −69.5% −29.7% 6.5%
Gross margin −60.5% 87.7% 19.4% 21.9% — 33.1% 62.0%
Operating margin <−999% <−999% −774.9% −625.9% −800.8% −435.6% −5.9%
Operating margin, 3-year average — <−999% <−999% −267.4% −378.5% −396.6% −7.4%
Net margin −467.1% <−999% −729.9% −545.2% −755.1% −430.4% −7.3%
Cash from operations / revenue <−999% <−999% −789.8% −353.0% −713.0% −224.5% 10.2%
Free-cash-flow margin <−999% <−999% −800.6% −353.0% −713.0% −224.5% 8.6%
Free-cash-flow margin, 3-year average — <−999% — −126.6% −309.9% −217.5% 7.4%
Stock pay / revenue 21.3% 257.1% 37.2% 466.2% 14.6% 65.9% 3.6%
Change in share count −93.4% 2.1% — >999% 25.2% 8.9% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -69.2% 10.0% 72 of 74
Change in growth rate Growth -166.6pp -0.3pp 71 of 74
Gross margin Profitability -60.5% 59.8% 58 of 59
Operating margin Profitability -1931.0% -5.9% 63 of 67
Net margin Profitability -467.1% -7.3% 67 of 75
Free-cash-flow margin Cash generation -3085.6% 10.1% 71 of 74
Change in share count Balance sheet -93.4% 1.5% 2 of 62
Days sales outstanding Balance sheet 1980 days 72 days 59 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$11,242
Institutions reporting
4
Shares held vs prior quarter
▲ 8100.0%
Positions opened / closed
4 / 1

Top buyers and sellers, Q2 2026: 4 institutions bought and 1 sold ; the biggest buyer was Integrated Wealth Concepts LLC (+600 shares) and the biggest seller Sbi Securities Co., Ltd (−10). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Integrated Wealth Concepts LLC $8,226 1K 73.2% New
UBS Group AG $2,811 0K 25.0% New
Wells Fargo & Company $178 0K 1.6% New
Morgan Stanley $27 0K 0.2% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Akanda Corp.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $40,650 1 trade by 1 insider, last 12 months Insider sales History → $10,150 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $30,500 net buying
Insider Date Trade Shares Price Value
Hrt Financial Lp 10% owner January 16, 2026 Sell 7,868 $1.29 $10,150
Hrt Financial Lp 10% owner January 15, 2026 Buy 29,036 $1.40 $40,650

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Akanda Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Akanda Corp. in brief

What does Akanda Corp. do?
Akanda Corp. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Akanda Corp.'s stock ticker?
Akanda Corp. trades under the ticker AKAN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Akanda Corp.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Akanda Corp. reported revenue of $258,075, 69.2% lower than a year earlier, according to its SEC filings.
What is Akanda Corp.'s free cash flow?
Akanda Corp.'s free-cash-flow margin is -3085.6% of revenue over the trailing twelve months, ranking 71 of the 74 pharmaceuticals companies we cover.
Who are Akanda Corp.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Integrated Wealth Concepts LLC, UBS Group AG and Wells Fargo & Company. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Akanda Corp.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Akanda Corp. are Scienture Holdings, Inc., 60 Degrees Pharmaceuticals, Inc., China SXT Pharmaceuticals, Inc., Lipocine Inc. and Nutriband Inc. The side-by-side comparison below sets their revenue, margins and growth against Akanda Corp.'s.
Are insiders buying or selling Akanda Corp. stock?
Over the last 12 months, Akanda Corp.'s directors and officers reported 1 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.